md-medicaldata

Authors

 

Ivana Minaković^1,2, Jelena Zvekić-Svorcan^1,3, Sandro Kopilović<sup>4,5

1</sup>University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia
²Health Center Novi Sad, Novi Sad, Serbia
³Special Hospital for Rheumatic Diseases, Novi Sad, Serbia
⁴Institute for Emergency Medicine, Novi Sad, Serbia
⁵Department of Scientific Research Education and International Cooperation, Novi Sad, Serbia

 

UDK: 616.71-007.233-085

The paper was received / Rad primljen: 18.02.2021.

Accepted / Rad prihvaćen: 28.02.2021.

 

Correspondence to:

Ivana Minaković,
University of Novi Sad, Faculty of Medicine,
Hajduk Veljkova 3, 21000 Novi Sad, Serbia,
e-mail: ivana.minakovic@uns.ac.rs

 

 

Abstract

 

Osteoporotic fractures are a significant cause of morbidity and mortality, and their annual prevalence is expected to increase due to population ageing and increased lifespan. Although the incidence of osteoporotic fractures can be reduced by 30-70% with regular use of pharmacotherapy, more than half of patients do not start therapy or do not use it appropriately. Medication non-adherence may be associated with worsening of disease symptoms, complications, increase in the frequency of hospitalizations and mortality. The results of various studies suggest an association between non-adherence in patients with osteoporosis and more complicated medication regimes, the severity of symptoms, personal perception of risk and benefits, patient knowledge and education, age, polypharmacy, side effects. It is important to identify risk factors associated with non-adherence and to achieveefficient communication between the patient and the healthcare providers to improve adherence and thus the outcome of the disease.

 

 

 

Keywords:

Anti-osteoporotic therapy; Adherence;  Osteoporosis; Predictors ofnon-adherence

 

 

 

Sažetak

Osteoporotski prelomi su značajan uzrok morbiditeta i mortaliteta, a očekuje se da će godišnja prevalenca ovakvih preloma rasti zbog starenja stanovništva i produženog životnog veka. Iako se redovnimkorišćenjem farmakoterapije učestalost osteoporotski preloma može smanjti za 30-70%, više od polovine pacijenata ne započinje da koristi terapiju, ili je ne koristi na odgovarajući način.Neadherenca terapiji može biti povezana sa simptomatskim pogoršanjem bolesti, komplikacijama, povećanjem učestalosti hospitalizacije i mortaliteta. Rezultati različitih studija ističu povezanost između neadherence terapiji i složenijih režima korišćenja lekova, težine simptoma, lične percepcije rizika i koristi, znanja i obrazovanja pacijenta, starosti, polifarmacije, neželjenih efekata. Važno je identifikovati faktore rizika povezane sa neadherencom i postići efikasnu komunikaciju između pacijenata i zdravstvenih radnika kako bi se poboljšala adherenca, a tako i ishod bolesti.

Ključne reči:

Antiosteoporotska terapija; Adherenca; Osteoporoza; Prediktori neadherence;

 

 

 

 

References:

1. Fatoye F, Smith P, Gebrye T, Yeowell G. Real-world persistence and adherence with oral bisphosphonates for osteoporosis: a systematic review. BMJ Open. 2019;9(4):e027049.
2. Compston JE, McClung MR, Leslie WD. Osteoporosis. Lancet. 2019;393:364–76.
3. Vučić Z, Bondžić N,Zvekić-Svorcan J. Quality of life in postmenopausal women with reduced bone mineral density. MD-Medical Data. 2018;10(3):143–7.
4. Štrangar E, Zvekić-Svorcan J.Risk evaluation in fragilefracture formation.MD-Medical Data. 2016;8(2):087–094.
5. Awasthi H, Mani D, Singh D, Gupta A. The underlying pathophysiology and therapeutic approaches for osteoporosis. Med Res Rev. 2018;38(6):2024–57.
6. Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey AB, Davidson KW, et al. Screening for Osteoporosis to Prevent Fractures. JAMA. 2018;319(24):2521–31.
7. Koller G, Goetz V, Vandermeer B, Homik J, McAlister FA, Kendler D. Persistence and adherence to parenteral osteoporosis therapies: a systematic review. Osteoporos Int. 2020;31(11):2093–102.
8. Yeam CT, Chia S, Tan HCC, Kwan YH, Fong W, Seng JJB. A systematic review of factors affecting medication adherence among patients with osteoporosis. Osteoporos Int. 2018;29(12):2623–37.
9. Wilton-Clark MS, Feasel AL, Kline GA, Billington EO. Autonomy begets adherence: decisions to start and persist with osteoporosis treatment after group medical consultation. Arch Osteoporos. 2020;15(1):138.
10. Straka I, Minár M, Škorvánek M, Grofik M, Danterová K, Benetin J, et al. Adherence to Pharmacotherapy in Patients With Parkinson’s Disease Taking Three and More Daily Doses of Medication. Front Neurol. 2019;10:799.
11. Cornelissen D, de Kunder S, Si L, Reginster JY, Evers S, Boonen A. Et al. Interventions to improve adherence to anti-osteoporosis medications: an updated systematic review. Osteoporos Int. 2020;31(9):1645–69.
12. Lemstra M, Nwankwo C, Bird Y, Moraros J. Primary nonadherence to chronic disease medications: a meta-analysis. Patient Prefer Adherence. 2018;12:721–31.
13. Kanis JA, Cooper C, Rizzoli R, Reginster, JY. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2019;30(1):3–44.
14. Walsh CA, Cahir C, Tecklenborg S, Byrne C, Culbertson MA, Bennett KE, et al. The association between medication non‐adherence and adverse health outcomes in ageing populations: A systematic review and meta‐analysis. Br J Clin Pharmacol Title. 2019;85(11):2464–78.
15. Gruszczyńska M, Wyszomirska J, Daniel-Sielańczyk A, Bąk-Sosnowska M. Selected psychological predictors of medication adherence in the older adults with chronic diseases. Nurs Open. 2020;8(1):317–26.
16. Qiao X, Tian X, Liu N, Dong L, Jin Y, et al. The association between frailty and medication adherence among community-dwelling older adults with chronic diseases: medication beliefs acting as mediators. Patient Educ Couns. 2020;130(12):2548–54.
17. Moon S J, Lee WY, Hwang JS, Hong YP,  Morisky DE. Accuracy of a screening tool for medication adherence: A systematic review and meta-analysis of the Morisky Medication Adherence Scale-8. PLOS ONE. 2017;12(11):e0187139.
18. Cheen MHH, Tan YZ, Oh LF, Wee HL, Thumboo J. Prevalence of and factors associated with primary medication non‐adherence in chronic disease: A systematic review and meta‐analysis. Int J Clin Pract. 2019;73(6):e13350.
19. Silverman S, Gold DT. Medication Decision-making in Osteoporosis: Can We Explain Why Patients Do Not Take Their Osteoporosis Medications? Curr Osteoporos Rep. 2018;16(6):772–4.
20. Spångeus A, Johansson S, Woisetschläger M. Adherence to and persistence with zoledronic acid treatment for osteoporosis—reasons for early discontinuation. Arch Osteoporos. 2020;15(1).
21. Donato P, Pepe J, Colangelo L, Danese V, Cecchetti V, Minisola S, Cipriani C. Adherence to bisphosphonates in the general population: a study in patients referred to a primary care service. Arch Osteoporos. 2019;14(1):42.
22. Paskins Z, Crawford-Manning F, Cottrell E, Corp N, Wright, J, Jinks C. Acceptability of bisphosphonates among patients, clinicians and managers: a systematic review and frameworksynthesis. BMJ Open. 2020;10(11):e0400634.
23. Gamboa A, Duaso E, Marimón P, Sandiumenge M, Escalante E, Lumbreras C, et al. Oral bisphosphonate prescription and non-adherence at 12 months in patients with hip fractures treated in an acute geriatric unit. Osteoporos Int. 2018;29(10):2309–14.
    

PDF 01-MD-Vol 13 No 1 2021_Minakovic et al